Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sulfapyridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.69 |
| ▸ | LMNA | P02545 | 5/20 | 0.69 |
| ▸ | POLB | P06746 | 1/20 | 0.66 |
| ▸ | AURKA | O14965 | 1/20 | 0.66 |
| ▸ | DHFR | P00374 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.59 |
| ▸ | ALPL | P05186 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.56 |
| ▸ | BRD4 | O60885 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfapyridine SCHEMBL668917 | 0.98 | SMN1; SMN2 (0.94) | SMN1; SMN2KDM4ELMNAPOLBAURKA | |
| Sulfapyridine SCHEMBL44219 | 0.98 | SMN1; SMN2 (1.00) | SMN1; SMN2KDM4ELMNAPOLBAURKA | |
| Sulfapyridine SCHEMBL29438089 | 0.98 | SMN1; SMN2 (1.00) | SMN1; SMN2KDM4ELMNAPOLBAURKA | |
| Sulfapyridine SCHEMBL27741790 | 0.97 | SMN1; SMN2 (0.97) | SMN1; SMN2KDM4ELMNAPOLBAURKA | |
| Sulfapyridine SCHEMBL3714634 | 0.97 | SMN1; SMN2 (0.97) | SMN1; SMN2KDM4ELMNAPOLBAURKA | |
| Sulfapyridine SCHEMBL11706483 | 0.97 | SMN1; SMN2 (0.97) | SMN1; SMN2KDM4ELMNAPOLBAURKA | |
| Sulfapyridine SCHEMBL27974729 | 0.95 | SMN1; SMN2 (0.94) | SMN1; SMN2KDM4ELMNAPOLBAURKA | |
| Sulfapyridine SCHEMBL11778484 | 0.94 | SMN1; SMN2 (0.91) | SMN1; SMN2KDM4ELMNAPOLBAURKA | |
| Sulfapyridine SCHEMBL28142861 | 0.92 | SMN1; SMN2 (0.88) | SMN1; SMN2KDM4ELMNAPOLBAURKA | |
| Sulfapyridine SCHEMBL2243590 | 0.87 | SMN1; SMN2 (0.79) | SMN1; SMN2KDM4ELMNAPOLBAURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108004346-B | Wheat gene Yr10 molecular marker and application thereof in screening wheat with wheat stripe rust resistance | 山东农业大学 | 2020-09-15 | — | — | CN | disclosed |
| US-10604783-B2 | Vibrio assay methods and kits | MISSISSIPPI STATE UNIVERSITY (US) | 2020-03-31 | — | — | US | disclosed |
| US-9278134-B2 | Dual functioning ionic liquids and salts thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150093778-A1 | VIBRIO ASSAY METHODS AND KITS | MISSISSIPPI STATE UNIVERSITY | 2015-04-02 | — | — | US | disclosed |
| US-8802596-B2 | Multi-functional ionic liquid compositions for overcoming polymorphism and imparting improved properties for active pharmaceutical, biological, nutritional, and energetic ingredients | BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2014-08-12 | — | — | US | disclosed |
| US-20120264605-A1 | Multi-Functional Ionic Liquid Compositions for Overcoming Polymorphism and Imparting Improved Properties for Active Pharmaceutical, Biological, Nutritional, and Energetic Ingredients | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120046244-A1 | DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2012-02-23 | — | — | US | disclosed |
| WO-2010078300-A1 | DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ALABAMA (US) | 2010-07-08 | — | — | WO | disclosed |
| EP-1438942-A1 | An otorhinological drug delivery device | Schering Oy (FI) | 2004-07-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264605-A1 | Multi-Functional Ionic Liquid Compositions for Overcoming Polymorphism and Imparting Improved Properties for Active Pharmaceutical, Biological, Nutritional, and Energetic Ingredients | SLC5A6, PNLIP, IPMK | SMN1; SMN2 742/4885KDM4E 4586/4885LMNA 1556/4885 |
| US-20120046244-A1 | DUAL FUNCTIONING IONIC LIQUIDS AND SALTS THEREOF | SLC6A6, SLC10A2, CLK2 | SMN1; SMN2 1096/4885KDM4E 4730/4885LMNA 2694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.